Sanofi’s fitusiran has had a rough road in hemophilia, weathering clinical holds and program halts tied to its lingering safety woes. Now, the drug is nearing the finish line with late-stage data in…
It’s no longer a secret that the US government is going to have to pay for Biogen’s new and expensive Alzheimer’s drug Aduhelm on the backs of huge increases in Medicare premiums. CMS explained last…
Last year, during the height of the biotech IPO boom, Generation Bio raised $230 million on a swing-for-the-fences approach to gene therapy. Launched out of UMass Medical School, the company promised…
After almost 40 years at Johnson & Johnson, head of global corporate affairs and communications Michael Sneed is retiring in April. Sneed has also served on the executive committee since 2018, and J&J…
A setback in Covid-19 didn’t stop Novartis from teaming up with Molecular Partners again. And this time, they will be looking for radiopharmaceuticals. Having bet big on the field, Novartis now wants…
Pfizer made a big splash in the M&A space Monday, announcing a $6.7 billion buyout of Arena Pharmaceuticals to chase Bristol Myers Squibb in the S1P race. But company execs suggested the company isn’t finished bringing on new assets. In an investor call outlining the Arena acquisition, chief business innovation…
Just two months after Moderna announced plans to build a $500 million mRNA vaccine factory in Africa, the biotech giant agreed
Raj Verma joined Sanofi exactly one year ago as the head of diversity, culture and experience as all three parts of his job title were adjusting to major changes because of the Covid-19 pandemic.…
A Boston-based provider of lab space is tripling its footprint with the addition of a West Coast campus. SmartLabs, a company with labs in three different neighborhoods in the Boston area, will open a…
As the investments in cell and gene therapy manufacturing continue to grow across the world, Cincinnati Children’s Hospital and CTI Clinical Trial & Consulting Services have entered a $100 million…
